•  MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1

  • Kisqali plus endocrine therapy had a median OS of nearly five years (58.7 months), the longest ever reported for premenopausal women with HR+/HER2- metastatic breast cancer (MBC), after a median of 53.5 months follow-up1

  • Kisqali …
  • At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies1

  • Despite advances in chronic myeloid leukemia (CML) care, many patients are at risk of disease …
  • Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1
  • Longer-term median follow-up of 40 months from the JULIET study showed a 33% two-year progression-free survival rate in patients with r/r DLBCL2
  • Both ELARA and JULIET trials reaffirm safety profile of Kymriah with no new short- or long-term safety signals identified

Basel, December 5, 2020 …

  • Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1
  • Chronic graft-versus-host disease (GvHD) is a life-threatening complication of stem cell transplants and half of patients become steroid refractory/dependent2,3
  • Findings from the study were presented

At Novartis, we know that our impact extends beyond the lives we touch with our medicines, and the performance we deliver for our stakeholders. We aim to have a positive impact on the communities in which we work, and build trust with society.

Our flagship Co-Creating Impact Summit on December 9, 2020, will provide an opportunity to build on the work we have already done in this area, and articulate the social, environmental and economic impact Novartis has on society, and on our planet.

With the rapidly changing ESG landscape, amplified by the COVID-19 pandemic, the upcoming …

In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.

In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.

Portrait picture of Nana, a sickle cell patient in Ghana

Novartis 2020 ASH Annual Meeting Virtual Portal

Novartis presence at ASH:

This annual event gives investors and industry analysts an opportunity to meet with Novartis executives who share deep insights into the company’s growth, pipeline and strategy.

We have delivered strong operational performance over the last three years and are positioned to maintain the momentum. The executives highlighted five assets that are growth drivers in major therapeutic areas, as well as five mid-to-late stage assets in Oncology and six mid-to-late stage assets in Pharmaceuticals with key milestones expected in 2021 and 2022.

We are also taking significant steps to …

  • Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies
  • Key growth drivers now contributing to 48% of Innovative Medicines sales; upcoming launches expected to lay the foundation for future sales expansion
  • Advancing leading pipeline based on scale, …